Sarepta Therapeutics Inc said on Wednesday it exercised its option to buy privately held gene therapy maker Myonexus Therapeutics Inc for $165 million.
Sarepta and Myonexus had entered into an exclusive partnership last May to develop Myonexus’ five gene therapy candidates for treating different forms of Limb-girdle muscular dystrophy, a group of muscle-wasting disorders.
As part of the deal, Sarepta had an exclusive option to acquire Myonexus.
Date: March 4, 2019
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: Yahoo Finance